Table 3.

Clinical antitumor activity

	Overall (n=27)	Cohort A (n=6)	Cohort B (n=21)
Confirmed objective response	15 (55.6)	2 (33.3)	13 (61.9)
Best overall response
Complete response	5 (18.6)	1 (16.7)	4 (19.0)
Partial response	10 (37)	1 (16.7)	9 (42.9)
Stable disease	10 (37)	3 (50.0)	7 (33.3)
Progressive disease	2 (7.4)	1 (16.7)	1 (4.8)
Disease control	25 (92.6)	5 (83.3)	20 (95.2)

Data are n (%), unless otherwise specified.

Responses were assessed in accordance with the Response Evaluation Criteria in Solid Tumors version 1.1.